title: Vaccine against Helicobacter pylori: Inevitable approach.
abstract: Over three decades have passed since the discovery of Helicobacter pylori (H. pylori), and yet many questions about its treatment remain unanswered. For example, there is no certainty regarding continued use of current antibiotic therapy against H. pylori. The bad news is that even combined regimens are also unable to eradicate bacterial colonization. The worst problem with H. pylori chemotherapy is that even if we identify the most successful regimen, it cannot eliminate the risk of re-infection. This problem is further complicated by the fact that clinicians have no information as to whether probiotics are useful or not. Moreover, to date, we have no large scale produced vaccine effective against H. pylori. Due to the relatively rapid and abundant dissemination of guidelines globally reported concerning management of gastric cancer prevention and therapeutic regimens, clinicians may choose a vaccine as better effective weapon against H. pylori. Therefore, a radical shift in adopted strategies is needed to guide ultimate decisions regarding H. pylori management. In light of failures in vaccine projects, we should identify better vaccine design targeting conserved/essential genes. The unique character and persistence of H. pylori pose obstacles to making an effective vaccine. Preferably, in developing countries, the best reasonable and logical approach is to recommend prophylactic H. pylori vaccine among children as an obligatory national program to limit primary colonization. Trying to produce a therapeutic vaccine would be postponed until later. In reality, we should not forget to prescribe narrow spectrum antibiotics. In the current review, I draw a route to define the best adopted strategy against this rogue bacterium.
authors.affiliation: Amin Talebi Bezmin Abadi, Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115-111, Iran.
authors.forename: Amin
authors.initials: A
authors.lastname: Talebi Bezmin Abadi
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D016481:Helicobacter Infections / Q000175:diagnosis / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D016480:Helicobacter pylori / Q000187:drug effects / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D019936:Probiotics / Q000627:therapeutic use; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines
keywords: Eradication; Helicobacter pylori; Probiotic; Vaccine